Cornerstone Wealth Management LLC Acquires 2,363 Shares of Johnson & Johnson (NYSE:JNJ)

Cornerstone Wealth Management LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 5.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 49,735 shares of the company’s stock after buying an additional 2,363 shares during the quarter. Cornerstone Wealth Management LLC’s holdings in Johnson & Johnson were worth $7,193,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. International Assets Investment Management LLC lifted its position in Johnson & Johnson by 20,130.0% during the 3rd quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock valued at $559,832,000 after purchasing an additional 3,437,397 shares during the period. Janus Henderson Group PLC increased its holdings in Johnson & Johnson by 228.1% in the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after purchasing an additional 2,356,359 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Johnson & Johnson by 11.4% in the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after acquiring an additional 1,729,281 shares during the last quarter. Holocene Advisors LP acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $225,040,000. Finally, FMR LLC grew its holdings in shares of Johnson & Johnson by 7.4% in the 3rd quarter. FMR LLC now owns 18,316,920 shares of the company’s stock valued at $2,968,440,000 after buying an additional 1,265,748 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.1 %

Johnson & Johnson stock opened at $146.76 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The stock has a market cap of $353.34 billion, a P/E ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51. The company’s 50-day moving average price is $147.85 and its two-hundred day moving average price is $156.06. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same quarter in the previous year, the business posted $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on JNJ shares. Leerink Partners decreased their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday. Wolfe Research started coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. Morgan Stanley dropped their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday. Bank of America reduced their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Raymond James decreased their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $170.06.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.